Conversations around persistent AF hybrid therapies: 1 Topic, 2 Continents, 3 Voices
The U.S. Food and Drug Administration (FDA) has recently approved the EPi-Sense® System to treat patients diagnosed with long-standing persistent atrial fibrillation (AF).
This is the only FDA approval of its kind—minimally invasive ablation therapy—patients with long-standing persistent atrial fibrillation (AF).
It significantly expands AF treatment options for this category of AF patients. With this therapy, the superiority trial showed a 35% difference in effectiveness at 18 months compared to endocardial RF ablation alone.
Incorporating both endocardial RF and epicardial therapies, the Hybrid AF Convergent procedure targets two areas where AF originates and creates transmural lesions that stop the onset of AF. This therapy may provide a long-term solution for appropriately selected patients with long-standing persistent AF.
This content was presented at EHRA 2021.
A John Camm
This webinar is supported by:
- Unmet treatment need in patients with advanced atrial fibrillation
- Importance of non-pulmonary vein triggers
- Evolution of Hybrid Convergent Therapy
- Discussion on the future of hybrid approaches
- Cardiothoracic Surgeons
A John Camm
John Camm is British Heart Foundation Professor of Clinical Cardiology (Emeritus) at St George’s University of London, London, UK. His interests include cardiac arrhythmias, atrial fibrillation, stroke prevention, and anticoagulation.
Professor Camm is Editor of the European Society of Cardiology Textbook of Cardiovascular Medicine and ESC CardioMed, Electrophysiology of the Heart, Clinical Cardiology and Evidence Based Cardiology. He has written or edited more than 40 books, predominantly in the field of cardiac arrhythmology. He has authored or co-authored more than 1450 peer reviewed papers, more than 500 book chapters, and in excess of 2500 accepted abstracts. He has delivered more than 1000 international lectures.
Professor Camm has been involved in the production of numerous guidelines, including the ESC guidelines for the management of atrial fibrillation
Dr Hugh Calkins is Professor of Cardiology and Director of the Electrophysiology Laboratory and Arrhythmia Service at the Johns Hopkins Hospital. He is an internationally recognized expert on catheter ablation, atrial fibrillation, syncope, arrhythmogenic right ventricular dysplasia (ARVD) and arrhythmia management.
He received his MD from Harvard before training in internal medicine at the Massachusetts General Hospital, and in cardiology and electrophysiology at Johns Hopkins. After completion of his cardiology fellowship he joined the faculty and received further training from Dr Fred Morady at the University of Michigan.
Dr Claudio Tondo is the chairman of the Heart Rhythm centre at Centro Cardiologico, University of Milan, Italy. Dr Tondo's interests range from clinical aspects of arrhythmias to genetics.